This story appears in the February issue of Utah Business. Subscribe.
The global fight against antibiotic-resistant bacteria has a new ally.
Business strategist Tony Robbins has stepped in to help battle the world’s worst superbugs by investing in EVŌQ Nano. What drew Robbins’ attention?
Our novel nanoparticle, EVQ-218, has the ability to kill bacteria from the inside without triggering antimicrobial resistance (AMR). AMR occurs when bacteria evolve to outsmart antibiotics, turning them into superbugs. Fueled by decades of antibiotic overuse and misuse, AMR is identified as a top 10 global health threat, contributing to almost 5 million deaths in 2019. In the United States alone, over $4.5 billion is spent each year treating antimicrobial-resistant infections.
EVŌQ Nano is uniquely positioned to help battle this growing health challenge thanks to our novel nanoparticle technology. Robbins frequently focuses his investments on innovative health technologies and understands the critical nature of what we bring to the fight against AMR.
“EVŌQ Nano’s advancements show a path toward solving some of the world’s most pressing challenges,” Robbins says. “From infrastructure resilience to sustainable agriculture, this platform shows the transformative impact of ingenuity in science and technology.”
Unlike traditional antimicrobial agents that often trigger AMR by rupturing bacterial cell walls, EVQ-218 employs a unique mechanism of action that kills bacteria from the inside. This prevents the activation of bacterial mutations that contribute to AMR.
Studies show EVQ-218 demonstrates efficacy against a range of harmful bacteria, including the top six antibiotic-resistant strains identified by the World Health Organization. Several applications are in development:
- Antimicrobial medical devices to defend against healthcare-associated infections, affecting more than 1 million patients annually.
- An inhaled therapeutic for the treatment of pulmonary bacterial infections in patients with cystic fibrosis.
- Textile surface treatments approved by the Environmental Protection Agency, free of chemicals, toxicity and environmental waste.
Beyond these applications, our nanotechnology platform has the potential to transform diverse industries in the near future, including protecting energy sector infrastructure from corrosion while boosting battery performance and longevity.
Robbins’ decision to join EVŌQ Nano as both an investor and strategic partner marks a major milestone in our journey. His global reach, business acumen and passion for improving lives align perfectly with our mission and will be instrumental in advancing the development of this pioneering technology.
